

Titus J Boggon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8551569/publications.pdf>

Version: 2024-02-01

130
papers

29,521
citations

24978

57
h-index

14156

128
g-index

132
all docs

132
docs citations

132
times ranked

34190
citing authors

#	ARTICLE	IF	CITATIONS
1	Tousled-like kinase 2 targets ASF1 histone chaperones through client mimicry. <i>Nature Communications</i> , 2022, 13, 749.	5.8	9
2	Lyso-PAF, a biologically inactive phospholipid, contributes to RAF1 activation. <i>Molecular Cell</i> , 2022, 82, 1992-2005.e9.	4.5	5
3	Constrained chromatin accessibility in PU.1-mutated agammaglobulinemia patients. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	31
4	Integrated genomic analyses of cutaneous T-cell lymphomas reveal the molecular bases for disease heterogeneity. <i>Blood</i> , 2021, 138, 1225-1236.	0.6	49
5	Cisplatin-mediated activation of glucocorticoid receptor induces platinum resistance via MAST1. <i>Nature Communications</i> , 2021, 12, 4960.	5.8	32
6	Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells. <i>Molecular Cell</i> , 2021, 81, 3833-3847.e11.	4.5	10
7	The pseudoGTPase group of pseudoenzymes. <i>FEBS Journal</i> , 2020, 287, 4232-4245.	2.2	14
8	The GTPase-activating protein p120RasGAP has an evolutionarily conserved "FLVR-unique" SH2 domain. <i>Journal of Biological Chemistry</i> , 2020, 295, 10511-10521.	1.6	8
9	Recognition of physiological phosphorylation sites by p21-activated kinase 4. <i>Journal of Structural Biology</i> , 2020, 211, 107553.	1.3	7
10	SH2 Domain Binding: Diverse FLVRs of Partnership. <i>Frontiers in Endocrinology</i> , 2020, 11, 575220.	1.5	20
11	Crystallographic Studies of the Cerebral Cavernous Malformations Proteins. <i>Methods in Molecular Biology</i> , 2020, 2152, 291-302.	0.4	1
12	Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 22730-22736.	3.3	52
13	Î ³ -6-Phosphogluconolactone, a Byproduct of the Oxidative Pentose Phosphate Pathway, Contributes to AMPK Activation through Inhibition of PP2A. <i>Molecular Cell</i> , 2019, 76, 857-871.e9.	4.5	39
14	Clamping Together Hemidesmosomes and Latching Them in Place. <i>Structure</i> , 2019, 27, 881-883.	1.6	1
15	Comprehensive profiling of the STE20 kinase family defines features essential for selective substrate targeting and signaling output. <i>PLoS Biology</i> , 2019, 17, e2006540.	2.6	41
16	Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer. <i>Cancer Discovery</i> , 2019, 9, 756-777.	7.7	18
17	ARGuing for a new kinase class. <i>Nature Chemical Biology</i> , 2019, 15, 431-432.	3.9	0
18	Mutations in ILK, encoding integrin-linked kinase, are associated with arrhythmogenic cardiomyopathy. <i>Translational Research</i> , 2019, 208, 15-29.	2.2	33

#	ARTICLE	IF	CITATIONS
19	Mutations in <i>TFAP2B</i> and previously unimplicated genes of the BMP, Wnt, and Hedgehog pathways in syndromic craniosynostosis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 15116-15121.	3.3	24
20	Crystal structures of p120RasGAP N-terminal SH2 domain in its apo form and in complex with a p190RhoGAP phosphotyrosine peptide. PLoS ONE, 2019, 14, e0226113.	1.1	13
21	CDC42 binds PAK4 via an extended GTPase-effector interface. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 531-536.	3.3	29
22	PAK4 crystal structures suggest unusual kinase conformational movements. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2018, 1866, 356-365.	1.1	11
23	The crystal structure of pseudokinase PEAK1 (Sugen kinase 269) reveals an unusual catalytic cleft and a novel mode of kinase fold dimerization. Journal of Biological Chemistry, 2018, 293, 1642-1650.	1.6	42
24	The N-Terminal GTPase Domain of p190RhoGAP Proteins Is a PseudoGTPase. Structure, 2018, 26, 1451-1461.e4.	1.6	10
25	PseudoGTPase domains in p190RhoGAP proteins: a mini-review. Biochemical Society Transactions, 2018, 46, 1713-1720.	1.6	7
26	MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. Cancer Cell, 2018, 34, 315-330.e7.	7.7	94
27	Targeting 6-phosphogluconate dehydrogenase in the oxidative PPP sensitizes leukemia cells to antimalarial agent dihydroartemisinin. Oncogene, 2017, 36, 254-262.	2.6	53
28	p190RhoGAP proteins contain pseudoGTPase domains. Nature Communications, 2017, 8, 506.	5.8	21
29	The repeat region of cortactin is intrinsically disordered in solution. Scientific Reports, 2017, 7, 16696.	1.6	9
30	Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E). Blood, 2017, 130, 1430-1440.	0.6	131
31	PAK6 targets to cell-cell adhesions via its N-terminus in a Cdc42-dependent manner to drive epithelial colony escape. Journal of Cell Science, 2016, 129, 380-93.	1.2	23
32	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension. Hepatology, 2016, 63, 1977-1986.	3.6	46
33	Structural Basis for Noncanonical Substrate Recognition of Cofilin/ADF Proteins by LIM Kinases. Molecular Cell, 2016, 62, 397-408.	4.5	44
34	Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 12238-12243.	3.3	181
35	Tetrameric Acetyl-CoA Acetyltransferase 1 Is Important for Tumor Growth. Molecular Cell, 2016, 64, 859-874.	4.5	73
36	Data publication with the structural biology data grid supports live analysis. Nature Communications, 2016, 7, 10882.	5.8	113

#	ARTICLE	IF	CITATIONS
37	Signaling, Regulation, and Specificity of the Type II p21-activated Kinases. <i>Journal of Biological Chemistry</i> , 2015, 290, 12975-12983.	1.6	51
38	Glutamate Dehydrogenase 1 Signals through Antioxidant Glutathione Peroxidase 1 to Regulate Redox Homeostasis and Tumor Growth. <i>Cancer Cell</i> , 2015, 27, 257-270.	7.7	269
39	The Strength and Cooperativity of KIT Ectodomain Contacts Determine Normal Ligand-Dependent Stimulation or Oncogenic Activation in Cancer. <i>Molecular Cell</i> , 2015, 57, 191-201.	4.5	26
40	Structural Basis for the Disruption of the Cerebral Cavemans 2 (CCM2) Interaction with Krev Interaction Trapped 1 (KRIT1) by Disease-associated Mutations. <i>Journal of Biological Chemistry</i> , 2015, 290, 2842-2853.	1.6	37
41	Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. <i>Molecular Cell</i> , 2015, 59, 345-358.	4.5	125
42	Genomic landscape of cutaneous T cell lymphoma. <i>Nature Genetics</i> , 2015, 47, 1011-1019.	9.4	347
43	AIP1 Expression in Tumor Niche Suppresses Tumor Progression and Metastasis. <i>Cancer Research</i> , 2015, 75, 3492-3504.	0.4	14
44	Structure of the ABL2/ARG kinase in complex with dasatinib. <i>Acta Crystallographica Section F, Structural Biology Communications</i> , 2015, 71, 443-448.	0.4	7
45	CCM2-CCM3 interaction stabilizes their protein expression and permits endothelial network formation. <i>Journal of Cell Biology</i> , 2015, 208, 987-1001.	2.3	46
46	Structural analysis of the KRIT1 ankyrin repeat and FERM domains reveals a conformationally stable ARD-FERM interface. <i>Journal of Structural Biology</i> , 2015, 192, 449-456.	1.3	12
47	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. <i>Nature Cell Biology</i> , 2015, 17, 1484-1496.	4.6	224
48	Structure and vascular function of MEK3-cerebral cavernous malformations 2 complex. <i>Nature Communications</i> , 2015, 6, 7937.	5.8	69
49	Discovery and Functional Validation of Novel Pediatric Specific FLT3 Activating Mutations in Acute Myeloid Leukemia: Results from the COG/NCI Target Initiative. <i>Blood</i> , 2015, 126, 87-87.	0.6	19
50	The cerebral cavernous malformations proteins. <i>Oncotarget</i> , 2015, 6, 32279-32280.	0.8	8
51	Cerebral cavernous malformation proteins at a glance. <i>Journal of Cell Science</i> , 2014, 127, 701-7.	1.2	89
52	Tyr-301 Phosphorylation Inhibits Pyruvate Dehydrogenase by Blocking Substrate Binding and Promotes the Warburg Effect. <i>Journal of Biological Chemistry</i> , 2014, 289, 26533-26541.	1.6	61
53	Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 253-262.	1.5	44
54	Two Amino Acid Residues Confer Different Binding Affinities of Abelson Family Kinase Src Homology 2 Domains for Phosphorylated Cortactin. <i>Journal of Biological Chemistry</i> , 2014, 289, 19704-19713.	1.6	12

#	ARTICLE	IF	CITATIONS
55	Tyr-94 Phosphorylation Inhibits Pyruvate Dehydrogenase Phosphatase 1 and Promotes Tumor Growth. <i>Journal of Biological Chemistry</i> , 2014, 289, 21413-21422.	1.6	50
56	Structural Determinants for Binding of Sorting Nexin 17 (SNX17) to the Cytoplasmic Adaptor Protein Krev Interaction Trapped 1 (KRIT1). <i>Journal of Biological Chemistry</i> , 2014, 289, 25362-25373.	1.6	23
57	Signaling pathways and the cerebral cavernous malformations proteins: lessons from structural biology. <i>Cellular and Molecular Life Sciences</i> , 2014, 71, 1881-1892.	2.4	67
58	Tyr Phosphorylation of PDP1 Toggles Recruitment between ACAT1 and SIRT3 to Regulate the Pyruvate Dehydrogenase Complex. <i>Molecular Cell</i> , 2014, 53, 534-548.	4.5	247
59	Differential binding to the ILK complex determines kindlin isoform adhesion localization and integrin activation. <i>Journal of Cell Science</i> , 2014, 127, 4308-21.	1.2	60
60	Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. <i>Nature Genetics</i> , 2014, 46, 1135-1139.	9.4	417
61	Lysine Acetylation Activates 6-Phosphogluconate Dehydrogenase to Promote Tumor Growth. <i>Molecular Cell</i> , 2014, 55, 552-565.	4.5	107
62	Global Analysis of Human Nonreceptor Tyrosine Kinase Specificity Using High-Density Peptide Microarrays. <i>Journal of Proteome Research</i> , 2014, 13, 4339-4346.	1.8	42
63	Identification of a Major Determinant for Serine-Threonine Kinase Phosphoacceptor Specificity. <i>Molecular Cell</i> , 2014, 53, 140-147.	4.5	91
64	Structural studies of cerebral cavernous malformations 2 (CCM2) reveal a folded helical domain at its C-terminus. <i>FEBS Letters</i> , 2013, 587, 272-277.	1.3	35
65	Structural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal region. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 17832-17837.	3.3	25
66	A Network of Interactions Enables CCM3 and STK24 to Coordinate UNC13D-Driven Vesicle Exocytosis in Neutrophils. <i>Developmental Cell</i> , 2013, 27, 215-226.	3.1	70
67	Mineralocorticoid Receptor Phosphorylation Regulates Ligand Binding and Renal Response to Volume Depletion and Hyperkalemia. <i>Cell Metabolism</i> , 2013, 18, 660-671.	7.2	152
68	Structure-guided studies of the SHP-1/JAK1 interaction provide new insights into phosphatase catalytic domain substrate recognition. <i>Journal of Structural Biology</i> , 2013, 181, 243-251.	1.3	13
69	Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 2916-2921.	3.3	275
70	Recessive loss of function of the neuronal ubiquitin hydrolase UCHL1 leads to early-onset progressive neurodegeneration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 3489-3494.	3.3	144
71	Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation. <i>Nature Communications</i> , 2013, 4, 1790.	5.8	75
72	Mechanism for KRIT1 Release of ICAP1-Mediated Suppression of Integrin Activation. <i>Molecular Cell</i> , 2013, 49, 719-729.	4.5	76

#	ARTICLE	IF	CITATIONS
73	p90 RSK2 Mediates Antiankist Signals by both Transcription-Dependent and -Independent Mechanisms. <i>Molecular and Cellular Biology</i> , 2013, 33, 2574-2585.	1.1	28
74	Cocrystal structure of the ICAP1 PTB domain in complex with a KRIT1 peptide. <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2013, 69, 494-498.	0.7	11
75	<scp>MERTK</scp> controls melanoma cell migration and survival and differentially regulates cell behavior relative to <scp>AXL</scp>. <i>Pigment Cell and Melanoma Research</i> , 2013, 26, 527-541.	1.5	44
76	RAC1 ^{P29S} is a spontaneously activating cancer-associated GTPase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 912-917.	3.3	146
77	Substrate and Inhibitor Specificity of the Type II p21-Activated Kinase, PAK6. <i>PLoS ONE</i> , 2013, 8, e77818.	1.1	19
78	Purification and SAXS Analysis of the Integrin Linked Kinase, PINCH, Parvin (IPP) Heterotrimeric Complex. <i>PLoS ONE</i> , 2013, 8, e55591.	1.1	12
79	SHP Family Protein Tyrosine Phosphatases Adopt Canonical Active-Site Conformations in the Apo and Phosphate-Bound States. <i>Protein and Peptide Letters</i> , 2013, 20, 1039-1048.	0.4	7
80	Structural Basis for Paxillin Binding and Focal Adhesion Targeting of Î²-Parvin. <i>Journal of Biological Chemistry</i> , 2012, 287, 32566-32577.	1.6	33
81	Calcium-induced Conformational Changes in C-terminal Tail of Polycystin-2 Are Necessary for Channel Gating. <i>Journal of Biological Chemistry</i> , 2012, 287, 17232-17240.	1.6	45
82	Structural Basis for Small G Protein Effector Interaction of Ras-related Protein 1 (Rap1) and Adaptor Protein Krev Interaction Trapped 1 (KRIT1). <i>Journal of Biological Chemistry</i> , 2012, 287, 22317-22327.	1.6	46
83	Type II p21-activated kinases (PAKs) are regulated by an autoinhibitory pseudosubstrate. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 16107-16112.	3.3	73
84	Phosphoglycerate Mutase 1 Coordinates Glycolysis and Biosynthesis to Promote Tumor Growth. <i>Cancer Cell</i> , 2012, 22, 585-600.	7.7	329
85	Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. <i>Nature Genetics</i> , 2012, 44, 1006-1014.	9.4	1,052
86	Lysozyme contamination facilitates crystallization of a heterotrimeric cortactin-Arg-lysozyme complex. <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2012, 68, 154-158.	0.7	11
87	Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. <i>Nature Genetics</i> , 2012, 44, 852-860.	9.4	1,049
88	Phosphoglycerate Mutase 1 Promotes Leukemia Metabolism by Coordinating Glycolysis and Biosynthesis, and Represents a Therapeutic Target in Leukemia Treatment. <i>Blood</i> , 2012, 120, 860-860.	0.6	1
89	Tyrosine Phosphorylation of Mitochondrial Pyruvate Dehydrogenase Kinase 1 Is Important for Cancer Metabolism. <i>Molecular Cell</i> , 2011, 44, 864-877.	4.5	278
90	The Use of Structural Biology in Janus Kinase Targeted Drug Discovery. <i>Current Drug Targets</i> , 2011, 12, 546-555.	1.0	49

#	ARTICLE	IF	CITATIONS
91	Molecular Recognition of Leucine-Aspartate Repeat (LD) Motifs by the Focal Adhesion Targeting Homology Domain of Cerebral Cavernous Malformation 3 (CCM3). <i>Journal of Biological Chemistry</i> , 2011, 286, 26138-26147.	1.6	35
92	Tyrosine Phosphorylation of Lactate Dehydrogenase A Is Important for NADH/NAD ⁺ Redox Homeostasis in Cancer Cells. <i>Molecular and Cellular Biology</i> , 2011, 31, 4938-4950.	1.1	193
93	EGFR-mutated lung cancer: a paradigm of molecular oncology. <i>Oncotarget</i> , 2010, 1, 497-514.	0.8	159
94	Structure of the EF-hand domain of polycystin-2 suggests a mechanism for Ca ²⁺ -dependent regulation of polycystin-2 channel activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 9176-9181.	3.3	78
95	Crystal Structure of CCM3, a Cerebral Cavernous Malformation Protein Critical for Vascular Integrity. <i>Journal of Biological Chemistry</i> , 2010, 285, 24099-24107.	1.6	75
96	Asymmetric receptor contact is required for tyrosine autophosphorylation of fibroblast growth factor receptor in living cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 2866-2871.	3.3	66
97	Stabilization of VEGFR2 Signaling by Cerebral Cavernous Malformation 3 Is Critical for Vascular Development. <i>Science Signaling</i> , 2010, 3, ra26.	1.6	148
98	Structural basis of competition between PINCH1 and PINCH2 for binding to the ankyrin repeat domain of integrin-linked kinase. <i>Journal of Structural Biology</i> , 2010, 170, 157-163.	1.3	19
99	Leukemogenic Tyrosine Kinases Inhibit PKM2 to Promote the Warburg Effect and Tumor Growth. <i>Blood</i> , 2010, 116, 3142-3142.	0.6	0
100	Genetic Abnormalities of the <i>EGFR</i> Pathway in African American Patients With Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5620-5626.	0.8	85
101	Analysis of the cytoplasmic interaction between polycystin-1 and polycystin-2. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 297, F1310-F1315.	1.3	30
102	Fibroblast Growth Factor Receptor 3 Associates with and Tyrosine Phosphorylates p90 RSK2, Leading to RSK2 Activation That Mediates Hematopoietic Transformation. <i>Molecular and Cellular Biology</i> , 2009, 29, 2105-2117.	1.1	53
103	Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity. <i>Oncogene</i> , 2009, 28, 518-533.	2.6	17
104	JAK3: A two-faced player in hematological disorders. <i>International Journal of Biochemistry and Cell Biology</i> , 2009, 41, 2376-2379.	1.2	76
105	Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth. <i>Science Signaling</i> , 2009, 2, ra73.	1.6	632
106	Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 1742-1751.	0.8	267
107	Domain Mapping of the Polycystin-2 C-terminal Tail Using de Novo Molecular Modeling and Biophysical Analysis. <i>Journal of Biological Chemistry</i> , 2008, 283, 28305-28312.	1.6	69
108	The structural basis of integrin-linked kinase-PINCH interactions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 20677-20682.	3.3	74

#	ARTICLE	IF	CITATIONS
109	Structural and numerical variation of FLT3/ITD in pediatric AML. <i>Blood</i> , 2008, 111, 4930-4933.	0.6	86
110	BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations. <i>PLoS Medicine</i> , 2007, 4, e315.	3.9	444
111	Automated Protein Crystallization Trials Using the Thermo Scientific Matrix Hydra II eDrop. <i>Journal of the Association for Laboratory Automation</i> , 2007, 12, 213-218.	2.8	7
112	Resistance to an Irreversible Epidermal Growth Factor Receptor (EGFR) Inhibitor in EGFR-Mutant Lung Cancer Reveals Novel Treatment Strategies. <i>Cancer Research</i> , 2007, 67, 10417-10427.	0.4	63
113	Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity. <i>Cancer Cell</i> , 2007, 11, 217-227.	7.7	933
114	Identification of Driver and Passenger Mutations of FLT3 by High-Throughput DNA Sequence Analysis and Functional Assessment of Candidate Alleles. <i>Cancer Cell</i> , 2007, 12, 501-513.	7.7	174
115	Identification of Driver and Passenger Mutations of FLT3 by High-Throughput DNA Sequence Analysis and Functional Assessment of Candidate Alleles.. <i>Blood</i> , 2007, 110, 206-206.	0.6	2
116	JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model. <i>Blood</i> , 2006, 108, 2770-2779.	0.6	104
117	Activating alleles of JAK3 in acute megakaryoblastic leukemia. <i>Cancer Cell</i> , 2006, 10, 65-75.	7.7	295
118	Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. <i>Blood</i> , 2005, 106, 996-1002.	0.6	158
119	Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. <i>Cancer Cell</i> , 2005, 7, 387-397.	7.7	2,695
120	EGFR Mutation and Resistance of Non-Small-Cell Lung Cancer to Gefitinib. <i>New England Journal of Medicine</i> , 2005, 352, 786-792.	13.9	3,715
121	Jak3 Kinase Domain Crystal Structures and Implications for Jak-Specific Drug Design.. <i>Blood</i> , 2005, 106, 69-69.	0.6	3
122	Structure and regulation of Src family kinases. <i>Oncogene</i> , 2004, 23, 7918-7927.	2.6	588
123	EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy. <i>Science</i> , 2004, 304, 1497-1500.	6.0	9,038
124	Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. <i>Blood</i> , 2004, 104, 1855-1858.	0.6	80
125	Apocrustacyanin C1 crystals grown in space and on earth using vapour-diffusion geometry: protein structure refinements and electron-density map comparisons. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2003, 59, 1117-1123.	2.5	10
126	C-Cadherin Ectodomain Structure and Implications for Cell Adhesion Mechanisms. <i>Science</i> , 2002, 296, 1308-1313.	6.0	616

#	ARTICLE	IF	CITATIONS
127	G-Protein Signaling Through Tubby Proteins. <i>Science</i> , 2001, 292, 2041-2050.	6.0	352
128	Screening for phasing atoms in protein crystallography. <i>Structure</i> , 2000, 8, R143-R149.	1.6	77
129	Purification, crystallization and initial X-ray analysis of the C1 subunit of the astaxanthin protein, V600, of the chondrophore <i>Velella velella</i> . <i>Acta Crystallographica Section D: Biological Crystallography</i> , 1999, 55, 266-268.	2.5	1
130	Bound-solvent structures for microgravity-, ground control-, gel- and microbatch-grown hen egg-white lysozyme crystals at 1.8 Å... resolution. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 1999, 55, 745-752.	2.5	45